ALLK - Allakos's SC lirentelimab shows encouraging action in early-stage study

Allakos (ALLK) has announced results from a Phase 1 study of subcutaneously ((SC)) administered lirentelimab (AK002) in healthy volunteers. Based on these results, Allakos intends to investigate monthly dosing of the SC formulation of lirentelimab in patients with eosinophilic gastritis, eosinophilic duodenitis, eosinophilic esophagitis and other diseases.Bioavailability of SC lirentelimab was 63% that was determined by comparing SC cohorts to cohorts that received intravenously ((IV)) administered lirentelimab, as well as resulted in extended eosinophil suppression at all dose levels tested through Day 85.Subcutaneously administered lirentelimab was well tolerated. Across all SC and IV lirentelimab cohorts there were no serious adverse events, no injection site reactions, no injection reactions and no infusion-related reactions. One subject receiving placebo reported an injection reaction (mild flushing two hours post-injection).

For further details see:

Allakos's SC lirentelimab shows encouraging action in early-stage study